

cof.c

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 19452A-000610US  
Client Ref. No.: SD 1999-158

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On May 4, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]  
Mark T. Davis



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jamey D. Marth, et al.

U.S. Patent No. 7,192,914 B1

Application No.: 10/089,525

Filed: October 7, 2002

For: PREVENTION OF  
ATHEROSCLEROSIS AND  
UNDESIRED BLOOD CLOTTING BY  
REDUCING VON WILLEBRAND  
FACTOR

Customer No.: 20350

Examiner: Jane J. Zara

Art Unit: 1635

REQUEST FOR CERTIFICATE OF  
CORRECTION

**Certificate**  
MAY 11 2007  
**of Correction**

Sir:

Pursuant to 37 CFR 1.322, Applicant submits a Request for Certificate of Correction correcting printing errors made at the time of printing of the patent. Applicant filed an Amendment After Allowance canceling claim 6, which was entered on February 13, 2007. Copies of both the Amendment and the Response are enclosed. The desired corrections are set forth on form PTO 1050, also enclosed. No fee is required for this Certificate.

Respectfully submitted,

[Signature]  
Kevin L. Bestian  
Reg. No. 34,744

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300  
KLB:mtd 61044097 v1

MAY 11 2007

(Also Form PTO-1050)

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.** : 7,192,914 B1  
**DATED** : March 20, 2007  
**INVENTOR(S)** : Jamey D. Marth, et al.

It is certified errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims, column 27, line 34, kindly change

"1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.

2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.

3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.

4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.

5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.

6. The method of claim 1, wherein platelet formation is not significantly affected by administration of the ST3Gal-IV sialyltransferase inhibitor to the animal.

**MAY 11 2007**

7. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.
  8. The method of claim 7, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
  9. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
  10. The method of claim 9, wherein the anti-cancer drug is tamoxifen.
  11. The method of claim 9, wherein the birth control agent is an estrogen or a progestin.
  12. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII."
- to
- 1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering
- to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.
2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.
  3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.
  4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.

5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.
6. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.
7. The method of claim 6, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
8. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
9. The method of claim 8, wherein the anti-cancer drug is tamoxifen.
10. The method of claim 8, wherein the birth control agent is an estrogen or a progestin.
11. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII."

**MAILING ADDRESS OF SENDER:**  
Kevin L. Bastian, Reg. No. 34,774  
Townsend and Townsend and Crew, LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834  
61044134 v1

**PATENT NO. 7,192,914 B1**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 19452A-000610US  
Client Ref. No.: SD 1999-158

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



On May 4, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]  
Mark T. Davis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jamey D. Marth, et al.

U.S. Patent No. 7,192,914 B1

Application No.: 10/089,525

Filed: October 7, 2002

For: PREVENTION OF  
ATHEROSCLEROSIS AND  
UNDESIREB BLOOD CLOTTING BY  
REDUCING VON WILLEBRAND  
FACTOR

Customer No.: 20350

Examiner: Jane J. Zara

Art Unit: 1635

REQUEST FOR CERTIFICATE OF  
CORRECTION

Sir:

Pursuant to 37 CFR 1.322, Applicant submits a Request for Certificate of Correction correcting printing errors made at the time of printing of the patent. Applicant filed an Amendment After Allowance canceling claim 6, which was entered on February 13, 2007. Copies of both the Amendment and the Response are enclosed. The desired corrections are set forth on form PTO 1050, also enclosed. No fee is required for this Certificate.

Respectfully submitted,

[Signature]  
Kevin L. Bastian  
Reg. No. 34,744

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300  
KLB:mtd 61044097 v1

MAY 11 2007

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

**PATENT NO.** : 7,192,914 B1  
**DATED** : March 20, 2007  
**INVENTOR(S)** : Jamey D. Marth, et al.

It is certified errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims, column 27, line 34, kindly change

- "1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.
2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.
3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.
4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.
5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.
6. The method of claim 1, wherein platelet formation is not significantly affected by administration of the ST3Gal-IV sialyltransferase inhibitor to the animal.

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 11 2007

7. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.
8. The method of claim 7, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
9. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
10. The method of claim 9, wherein the anti-cancer drug is tamoxifen.
11. The method of claim 9, wherein the birth control agent is an estrogen or a progestin.
12. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII."

to

--1. A method for decreasing levels of vWF or FVIII in an animal, the method comprising administering

to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Williebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.

2. The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.
3. The method of claim 2, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.
4. The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.

5. The method of claim 4, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.
6. The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.
7. The method of claim 6, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.
8. The method of claim 2, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.
9. The method of claim 8, wherein the anti-cancer drug is tamoxifen.
10. The method of claim 8, wherein the birth control agent is an estrogen or a progestin.
11. A method for modulating levels of vWF or FVIII in an animal, the method comprising administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and monitoring the animal for levels of vWF or FVIII."

**MAILING ADDRESS OF SENDER:**  
Kevin L. Bastian, Reg. No. 34,774  
Townsend and Townsend and Crew, LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834  
61044134 v1

**PATENT NO. 7,192,914 B1**





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



NVS, SE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/089,525

10/07/2002

Jamey D Marth

19452A-6-IUS

9242

20350 7590 02/13/2007  
TOWNSEND AND TOWNSEND AND CREW, LLP  
TWO EMBARCADERO CENTER  
EIGHTH FLOOR  
SAN FRANCISCO, CA 94111-3834

EXAMINER

ZARA, JANE J

ART UNIT

PAPER NUMBER

1635

MAIL DATE

DELIVERY MODE

02/13/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

MAY 11 2007

TDB

Art Unit: 1635

## **DETAILED ACTION**

### ***Response to Amendment***

The amendment filed on 1-30-07 under 37 CFR 1.312 has been entered.

### ***Conclusion***

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Douglas Schultz, can be reached on (571) 272-0763. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

**MAY 11 2007**

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jane Zara  
2-8-07

*J Zara*  
*+C1600*

JANE ZARA, PH.D.  
PRIMARY EXAMINER

MAY 11 2007



## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1478211
<b>Application Number:</b>	10089525
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9242
<b>Title of Invention:</b>	PREVENTION OF ATHEROSCLEROSIS AND UNDESIREB BLOOD CLOTTING BY REDUCING VON WILLEBRAND FACTOR
<b>First Named Inventor/Applicant Name:</b>	Jamey D Marth
<b>Customer Number:</b>	20350
<b>Filer:</b>	Nicholas V. Sherbina/Jocelyn Eskow
<b>Filer Authorized By:</b>	Nicholas V. Sherbina
<b>Attorney Docket Number:</b>	19452A-6-1US
<b>Receipt Date:</b>	30-JAN-2007
<b>Filing Date:</b>	07-OCT-2002
<b>Time Stamp:</b>	19:29:11
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----


### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1		19452A-000610US_Amend_after_allowance_1-30-07.PDF	143055	yes	6

MAY 11 2007

	<b>Multipart Description/PDF files in .zip Description</b>		
	<b>Document Description</b>	<b>Start</b>	<b>End</b>
	Miscellaneous Incoming Letter	1	1
	Amendment after Notice of Allowance (Rule 312)	2	6
<b>Warnings:</b>			
<b>Information:</b>			
<b>Total Files Size (in bytes):</b>		143055	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>			

MAY 11 2007



PTO/SB/21 (07-08)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/089,525
	Filing Date	October 7, 2002
	First Named Inventor	Marth, Jamey D.
	Art Unit	1635
	Examiner Name	Jane J. Zara
Total Number of Pages in This Submission	Attorney Docket Number	19452A-000610US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment After Allowance Under 37 C.F.R. 1.312	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<b>Remarks</b> The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	Nicholas V. Sherbina		
Date	January 30, 2007	Reg. No.	54,443

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office on the date shown below.			
Signature			
Typed or printed name	Jocelyn A. Eskow	Date	January 30, 2007

MAY 11 2007

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on January 30, 2007

By: Jamie Egan



PATENT

Attorney Docket No.: 19452A-000610US

Client Ref. No.: SD 1999-158

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

JAMEY D MARTH *et al.*

Application No.: 10/089,525

Filed: October 7, 2002

For: PREVENTION OF  
ATHEROSCLEROSIS AND  
UNDESIRED BLOOD  
CLOTTING BY REDUCING  
VON WILLEBRAND FACTOR

Customer No.: 20350

Conf. No.: 9242

Examiner: Jane J. Zara

Art Unit: 1635

AMENDMENT AFTER ALLOWANCE  
UNDER 37 CFR § 1.312

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.

MAY 11 2007

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) A method for decreasing levels of vWF or FVIII in an animal, the method comprising

administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and said animal is suffering from atherosclerosis or a blood clotting disorder, and whereby levels of von Willebrand factor (vWF) or factor VIII (FVIII) in the animal are decreased.

2-5. (Canceled)

6. (Previously presented) The method of claim 1, wherein the method is performed in conjunction with administration of a drug for which blood clotting is a potential side effect.

7. (Previously presented) The method of claim 6, wherein the ST3Gal-IV sialyltransferase inhibitor is administered before or simultaneously with the drug for which blood clotting is a potential side effect.

8-9. (Canceled)

10. (Previously presented) The method of claim 1, wherein the method is performed as a therapeutic measure against atherosclerosis.



11. (Original) The method of claim 10, wherein the atherosclerosis is associated with coronary artery disease or peripheral arterial disease.

12. (Canceled)

13-28. (Canceled)

29. (Previously presented) The method of claim 1, further comprising monitoring the animal for levels of vWF or FVIII.

30. (Previously presented) The method of claim 29, further comprising adjusting the dose of the ST3Gal-IV sialyltransferase inhibitor to maintain vWF at a desired level.

31-36. (Canceled)

37. (Previously presented) The method of claim 6, wherein the drug for which blood clotting is a potential side effect is selected from the group consisting of an anti-cancer drug, a corticosteroid, raloxifene, and a birth control agent.

38. (Previously presented) The method of claim 37, wherein the anti-cancer drug is tamoxifen.

39. (Previously presented) The method of claim 37, wherein the birth control agent is an estrogen or a progestin.

40. (Previously presented) A method for modulating levels of vWF or FVIII in an animal, the method comprising  
administering to the animal an effective dose of an inhibitor of ST3Gal-IV sialyltransferase enzyme activity, wherein said inhibitor is an analog of a ST3Gal-IV substrate and whereby levels of vWF or FVIII in the animal are decreased; and  
monitoring the animal for levels of vWF or FVIII.

NOV 11 2007

**REMARKS/ARGUMENTS**

Upon entry of this amendment, claim 12 is canceled without prejudice or disclaimer. Applicants reserve the right to pursue the subject matter of claim 12 in a related, co-pending application.


**CONCLUSION**

Entry of this amendment is respectfully urged since it merely cancels one of the claims and does not touch the merits.

Respectfully submitted,

Dated: January 30, 2007

By:

  
Nicholas V. Sherbina  
Reg. No. 54,443

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 206-467-9600  
Fax: 415-576-0300  
NVS:jae  
60968731 v1

MAY 11 2007